Loading...
•
Sep 30, 2021
Syndax Q3 2021 Earnings Report
Syndax reported financial results and provided a clinical and business update.
Key Takeaways
Syndax Pharmaceuticals reported its Q3 2021 financial results, highlighting the initiation of the pivotal Phase 2 portion of the SNDX-5613 AUGMENT-101 trial and a global collaboration with Incyte for axatilimab. Updated data from SNDX-5613 and axatilimab clinical programs will be presented at the ASH Annual Meeting.
Pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial was initiated in patients with NPM1 and MLLr acute leukemias.
Global collaboration with Incyte was entered to develop and commercialize axatilimab for cGVHD and other fibrotic diseases.
Updated data from SNDX-5613 and axatilimab clinical programs will be presented at the 63rd ASH Annual Meeting.
A new trial to assess the anti-leukemic efficacy of SNDX-5613 in NPM1 or MLLr patients with measurable residual disease (MRD) progression following initial treatment planned.
Forward Guidance
Syndax provided financial guidance for the full year of 2021.
Positive Outlook
- R&D expenses are expected to be $90 to $100 million.
- Total operating expenses are expected to be $110 to $120 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...